Clinical Trial: A Phase 1 Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07776782) titled 'A Phase 1 Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants' on Aug. 17.

Brief Summary: A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants

Study Start Date: July 16

Study Type: INTERVENTIONAL

Condition: Healthy Volunteer

Intervention: DRUG: MT-201

MT-201 and Infliximab

Recruitment Status: RECRUITING

Sponsor: Mirador Therapeutics, Inc.

Disclaimer: Curated by HT Syndication....